Literature DB >> 30080841

A backpack revs up T-cell activity.

Thomas Shum1, Helen E Heslop1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30080841     DOI： 10.1038/nbt.4215

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  10 in total

Review 1.  T cell exclusion, immune privilege, and the tumor microenvironment.

Authors:  Johanna A Joyce; Douglas T Fearon
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

2.  Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.

Authors:  Peter R Rhode; Jack O Egan; Wenxin Xu; Hao Hong; Gabriela M Webb; Xiaoyue Chen; Bai Liu; Xiaoyun Zhu; Jinghai Wen; Lijing You; Lin Kong; Ana C Edwards; Kaiping Han; Sixiang Shi; Sarah Alter; Jonah B Sacha; Emily K Jeng; Weibo Cai; Hing C Wong
Journal:  Cancer Immunol Res       Date:  2015-10-28       Impact factor: 11.151

3.  Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma.

Authors:  Ling Zhang; Richard A Morgan; Joal D Beane; Zhili Zheng; Mark E Dudley; Sadik H Kassim; Azam V Nahvi; Lien T Ngo; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Steven A Feldman; Mary Ann Toomey; Sid P Kerkar; Nicholas P Restifo; James C Yang; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2015-02-18       Impact factor: 12.531

4.  IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner.

Authors:  Rebecca Berlant Liu; Boris Engels; Karin Schreiber; Cezary Ciszewski; Andrea Schietinger; Hans Schreiber; Bana Jabri
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-01       Impact factor: 11.205

5.  Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.

Authors:  M J Robertson; C Cameron; M B Atkins; M S Gordon; M T Lotze; M L Sherman; J Ritz
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

6.  Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes.

Authors:  Jonathan T Sockolosky; Eleonora Trotta; Giulia Parisi; Lora Picton; Leon L Su; Alan C Le; Akanksha Chhabra; Stephanie L Silveria; Benson M George; Indigo C King; Matthew R Tiffany; Kevin Jude; Leah V Sibener; David Baker; Judith A Shizuru; Antoni Ribas; Jeffrey A Bluestone; K Christopher Garcia
Journal:  Science       Date:  2018-03-02       Impact factor: 47.728

7.  Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.

Authors:  Thomas Shum; Bilal Omer; Haruko Tashiro; Robert L Kruse; Dimitrios L Wagner; Kathan Parikh; Zhongzhen Yi; Tim Sauer; Daofeng Liu; Robin Parihar; Paul Castillo; Hao Liu; Malcolm K Brenner; Leonid S Metelitsa; Stephen Gottschalk; Cliona M Rooney
Journal:  Cancer Discov       Date:  2017-08-22       Impact factor: 39.397

8.  A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.

Authors:  Yuki Kagoya; Shinya Tanaka; Tingxi Guo; Mark Anczurowski; Chung-Hsi Wang; Kayoko Saso; Marcus O Butler; Mark D Minden; Naoto Hirano
Journal:  Nat Med       Date:  2018-02-05       Impact factor: 53.440

9.  Therapeutic cell engineering with surface-conjugated synthetic nanoparticles.

Authors:  Matthias T Stephan; James J Moon; Soong Ho Um; Anna Bershteyn; Darrell J Irvine
Journal:  Nat Med       Date:  2010-08-15       Impact factor: 53.440

10.  Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.

Authors:  Mauro P Avanzi; Oladapo Yeku; Xinghuo Li; Dinali P Wijewarnasuriya; Dayenne G van Leeuwen; Kenneth Cheung; Hyebin Park; Terence J Purdon; Anthony F Daniyan; Matthew H Spitzer; Renier J Brentjens
Journal:  Cell Rep       Date:  2018-05-15       Impact factor: 9.423
  10 in total
  1 in total

1.  In vivo hitchhiking of immune cells by intracellular self-assembly of bacteria-mimetic nanomedicine for targeted therapy of melanoma.

Authors:  Cheng Gao; Qingfu Wang; Junyan Li; Cheryl H T Kwong; Jianwen Wei; Beibei Xie; Siyu Lu; Simon M Y Lee; Ruibing Wang
Journal:  Sci Adv       Date:  2022-05-11       Impact factor: 14.957
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.